Bevacizumab biosimilar - International Biotech Center Generium

Drug Profile

Bevacizumab biosimilar - International Biotech Center Generium

Alternative Names: Apagin; AT-001 - IBCG; Fully humanised monoclonal antibody to VEGF; GNR-011; R-84

Latest Information Update: 18 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Peregrine Pharmaceuticals; University of Texas Southwestern Medical Center
  • Developer Affitech Research AS
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Breast cancer; Colorectal cancer; Eye disorders; Glioblastoma; Non-small cell lung cancer

Most Recent Events

  • 26 Oct 2015 Phase-II/III clinical trials in Breast cancer in Russia (IV) before October 2015
  • 26 Oct 2015 Phase-II/III clinical trials in Colorectal cancer in Russia (IV) before October 2015
  • 26 Oct 2015 Phase-II/III clinical trials in Eye disorders in Russia (IV) before October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top